Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Biologics vs placebo Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 3 studies · 197 participants | Very low |
Biologics vs placebo Withdrawals due to adverse events 12 to 44 weeks · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.55 [0.88, 2.74] | 8 studies · 792 participants | Low |
Cromolyn sodium vs placebo Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Clinical improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Cromolyn sodium vs placebo Histological improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 15 participants | Low |
Cromolyn sodium vs placebo Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Withdrawals due to adverse events at 8 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.27 [0.01, 5.7] | 1 study · 16 participants | Low |
PGD2R antagonist OC000459 vs placebo Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Histological improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 11.94 [6.56, 21.75] | 12 studies · 978 participants | High |
PGD2R antagonist OC000459 vs placebo Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
PGD2R antagonist OC000459 vs placebo Histological improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Histological improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
PGD2R antagonist OC000459 vs placebo Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
PGD2R antagonist OC000459 vs placebo Withdrawals due to adverse events · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Swallowed fluticasone vs oral prednisone Clinical improvement at 4 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.09 [0.9, 1.33] | 1 study · 80 participants | Very low |
Swallowed fluticasone vs oral prednisone Clinical improvement at 4 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Swallowed fluticasone vs oral prednisone Histological improvement at 4 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.1 [0.87, 1.38] | 1 study · 80 participants | Very low |
Swallowed fluticasone vs oral prednisone Histological improvement at 4 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 68 participants | Very low |
Corticosteroids vs placebo Histological improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 5 studies · 449 participants | Low |
Swallowed fluticasone vs oral prednisone Endoscopic improvement at 4 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.13 [0.91, 1.41] | 1 study · 80 participants | Very low |
Swallowed fluticasone vs oral prednisone Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Swallowed fluticasone vs oral prednisone Withdrawals due to adverse events at 4 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.5 [0.16, 1.53] | 1 study · 80 participants | Very low |
Oral viscous budesonide vs swallowed fluticasone Clinical improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral viscous budesonide vs swallowed fluticasone Clinical improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 84 participants | Low |
Oral viscous budesonide vs swallowed fluticasone Histological improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.13 [0.84, 1.51] | 1 study · 129 participants | Low |
Oral viscous budesonide vs swallowed fluticasone Histological improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 111 participants | Low |
Oral viscous budesonide vs swallowed fluticasone Endoscopic improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral viscous budesonide vs swallowed fluticasone Endoscopic improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 111 participants | Low |
Oral viscous budesonide vs swallowed fluticasone Withdrawals due to adverse events at 8 weeks · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.98 [0.42, 2.32] | 1 study · 129 participants | Low |
Corticosteroids vs placebo Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 2.6 [0.82, 8.19] | 3 studies · 102 participants | Low |
Esomeprazole vs fluticasone Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Clinical improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 2 studies · 67 participants | Very low |
Esomeprazole vs fluticasone Histological improvement at 8 weeks (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.62 [0.77, 3.41] | 2 studies · 72 participants | Very low |
Esomeprazole vs fluticasone Histological improvement at 8 weeks (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 2 studies · 70 participants | Very low |
Esomeprazole vs fluticasone Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Withdrawals due to adverse events at 8 weeks · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.95 [0.07, 13.38] | 2 studies · 72 participants | Very low |
One‐food elimination diet vs four‐food elimination diet Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Clinical improvement at 12 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 50 participants | Very low |
One‐food elimination diet vs four‐food elimination diet Histological improvement at 12 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 2.26 [1.15, 4.43] | 1 study · 63 participants | Very low |
Corticosteroids vs placebo Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 5 studies · 596 participants | Low |
One‐food elimination diet vs four‐food elimination diet Histological improvement at study endpoint (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Endoscopic improvement at study endpoint (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Endoscopic improvement at 12 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 34 participants | Very low |
One‐food elimination diet vs four‐food elimination diet Withdrawals due to adverse events at 12 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.33 [0.11, 0.98] | 1 study · 63 participants | Very low |
One‐food elimination diet vs six‐food elimination diet Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs six‐food elimination diet Clinical improvement at 6 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 129 participants | Very low |